Dermatology
Latest news
109 articles · 20 / page
Bio-Engineered Autologous Skin Grafts Outperform Gold Standard in Burn Care: 1-Year Phase IIB Results
A Phase IIB trial demonstrates that denovoSkin™, an autologous bio-engineered skin graft, offers a significantly higher expansion ratio and superior scar outcomes compared to split-thickness skin grafts in burn patients, potentially revolut
EMG-Guided Botulinum Toxin Injections Significantly Reduce Pain and Improve Sexual Function in Provoked Vestibulodynia
A randomized double-blind trial reveals that EMG-guided Onabotulinum toxin A injections effectively alleviate pain and enhance quality of life and sexual satisfaction in women with provoked vestibulodynia, supporting the role of muscular hy
Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking
Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemi
PROMIS Measures Proven Valid and Responsive for Assessing the Multidimensional Impact of Chronic Skin Diseases
A cohort study validates PROMIS measures for anxiety, depression, and social impact in chronic skin diseases, demonstrating that these standardized tools are reliable for tracking physical and social outcomes in clinical dermatology setting
Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
Low-Dose Interleukin-2 Accelerates Disease Control and May Spare Steroids in Moderate-to-Severe Bullous Pemphigoid
A single-center perspective-controlled trial found subcutaneous low-dose IL-2 plus corticosteroids achieved faster disease control in moderate-to-severe bullous pemphigoid and reduced total steroid exposure without serious infections, suppo
Rocatinlimab (OX40 blockade) delivers clinically meaningful benefit in moderate-to-severe atopic dermatitis: results from ROCKET-IGNITE and ROCKET-HORIZON
Two global phase 3 trials show rocatinlimab, an anti‑OX40 therapy, produced statistically significant improvements in EASI‑75 and vIGA‑AD 0/1 at 24 weeks versus placebo with a generally acceptable safety profile.
Predicting Rare but Serious Harm: A Validated 100‑Day Risk Model for Allopurinol‑Induced Severe Cutaneous Adverse Reactions
A large UK cohort study developed and externally validated a 100‑day prognostic model for allopurinol‑induced severe cutaneous adverse reactions (SCAR). Key predictors include age, CKD stage, high initial dose, and Asian ethnicity; discrimi
Standardizing How Clinicians See Hidradenitis Suppurativa: Key Consensus on Lesion Definitions and Investigator Guidance from a Modified Delphi Exercise
An international Delphi consensus produced standardized morphological definitions and practical guidance to improve investigator lesion assessment in hidradenitis suppurativa clinical trials, enhancing reliability and trial data quality.
Standardizing How Investigators Identify Hidradenitis Suppurativa Lesions: Key Findings from a Modified Delphi Consensus
A multidisciplinary Delphi panel produced consensus morphological definitions and practical guidance to standardize investigator lesion assessments in hidradenitis suppurativa (HS) clinical trials — improving reliability of endpoints such a
Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma
The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short m
Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Distinct Clinical Entity
Lupuslike manifestations linked with MDS and CMML differ greatly from classic lupus, featuring unique clinical and molecular traits and often requiring clone-directed treatment rather than standard lupus therapies.
Seborrheic Dermatitis and Epithelial Barrier Diseases: Large Cohort Studies Support a Shared Barrier‑Driven Pathogenesis
Two large US retrospective cohort studies show seborrheic dermatitis is strongly associated with a range of epithelial barrier diseases (skin, respiratory, gastrointestinal, ocular), with evidence of bidirectional risk. Findings support the
Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship
A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting
Intimacy, Intranasal Oxytocin, and Faster Wound Healing: A Randomized Trial Linking Touch, Sex, and Neuroendocrine Recovery
A double‑blind RCT in 160 healthy adults found that intranasal oxytocin combined with structured positive interaction and daily physical intimacy (affectionate touch, sex) was associated with reduced cortisol and modestly faster dermatologi
Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial
The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectabl
Dual IL‑17A/IL‑17F blockade with sonelokimab produces robust clinical responses in active psoriatic arthritis: phase 2 randomized trial
A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable sh
Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism
A large FAERS analysis links immune checkpoint inhibitors (ICIs) to markedly increased SJS/TEN risk, demonstrates additive synergy with high‑risk small molecules, and shows delayed latency particularly with anti–PD‑1 agents — supporting a t
Browse by specialty
Open language-specific specialty feeds and department pages.